PRDM16调节平滑肌肉细胞的身份和动脉样硬化斑块组成
Josephine M E Tan1,2,3, Lan Cheng4,5, Ryan P Calhoun4,5
1Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania, Philadelphia, PA, USA. j.m.e.tan@amsterdamumc.nl.
Nature cardiovascular research
|October 17, 2025
概括
PRDM16抑制了血管光滑肌细胞 (SMC) 的合成表型. 失去PRDM16促进了动脉样硬化中的合成SMC,影响了斑块组成和心血管疾病的进展.
科学领域:
- 心血管生物学 心血管生物学
- 细胞生物学 细胞生物学
- 分子遗传学 分子遗传学
背景情况:
- 血管光滑肌细胞 (SMCs) 在动脉样硬化等病理条件下切换表型.
- "合成"的SMC表型,以迁移,增殖和矩阵生产为特征,有助于动脉样硬化病变的发展.
- 调节合成SMC表型的机制尚未完全理解.
研究的目的:
- 为了确定合成血管光滑肌肉细胞表型的关键调节者.
- 研究PRDM16在SMC表型切换和动脉样硬化斑块形成中的作用.
主要方法:
- 在血管光滑肌细胞中的基因表达分析.
- 在小鼠模型中对PRDM16进行基因操纵.
- 在体内评估动脉样硬化斑块特征.
- 染色体免疫沉测试以确定PRDM16结合部位.
主要成果:
- PRDM16作为合成SMC表型的转录抑制剂.
- 在SMC调制过程中,PRDM16的表达减少.
- 缺乏PRDM16促进了合成的SMC程序,增加纤维增殖性斑块和减少动脉样硬化中的泡细胞.
- 过度表达PRDM16可以抑制SMC的迁移,增殖和纤维化.
结论:
- PRDM16是血管光滑肌肉细胞命运的关键守门员.
- 通过控制SMC表型,PRDM16在调节动脉样硬化斑块组成方面发挥着重要作用.
- 准PRDM16可能为心血管疾病提供治疗策略.
更多相关视频
08:28Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro
Published on: February 15, 2022
4.2K
10:57Using In Vivo and Tissue and Cell Explant Approaches to Study the Morphogenesis and Pathogenesis of the Embryonic and Perinatal Aorta
Published on: September 12, 2017
8.9K
相关概念视频
01:30Atherosclerosis I: Introduction
738
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
738
01:26Coronary Artery Disease II: Pathophysiology
332
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
332
01:26Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
01:38Inflammation
61.4K
Overview
61.4K